Literature DB >> 32730786

Global hepatitis C elimination: an investment framework.

Alisa Pedrana1, Jessica Howell2, Nick Scott3, Sophia Schroeder3, Christian Kuschel4, Jeffrey V Lazarus5, Rifat Atun6, Ricardo Baptista-Leite7, Ellen 't Hoen8, Sharon J Hutchinson9, Lisa Aufegger10, Raquel Peck11, Annette H Sohn12, Tracy Swan13, Mark Thursz14, Olufunmilayo Lesi15, Manik Sharma16, John Thwaites17, David P Wilson3, Margaret Hellard18.   

Abstract

WHO has set global targets for the elimination of hepatitis B and hepatitis C as a public health threat by 2030. However, investment in elimination programmes remains low. To help drive political commitment and catalyse domestic and international financing, we have developed a global investment framework for the elimination of hepatitis B and hepatitis C. The global investment framework presented in this Health Policy paper outlines national and international activities that will enable reductions in hepatitis C incidence and mortality, and identifies potential sources of funding and tools to help countries build the economic case for investing in national elimination activities. The goal of this framework is to provide a way for countries, particularly those with minimal resources, to gain the substantial economic benefit and cost savings that come from investing in hepatitis C elimination.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32730786     DOI: 10.1016/S2468-1253(20)30010-8

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  5 in total

1.  Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study.

Authors:  Jessica Howell; Huy Van; Minh Pham; Rohit Sawhney; Fan Li; Purnima Bhat; John Lubel; William Kemp; Stephen Bloom; Avik Majumdar; Geoff McCaughan; Samuel Hall; Timothy Spelman; Joseph S Doyle; Margaret Hellard; Kumar Visvanathan; Alexander J Thompson; Heidi E Drummer; David Anderson
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-10-10

2.  Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.

Authors:  Dr Nick Scott; Ms Anna Palmer; Mr Tom Tidhar; Prof Mark Stoove; Dr Rachel S Sacks-Davis; A/Prof Joseph S Doyle; Dr Alisa J Pedrana; Prof Alexander Thompson; Prof David P Wilson; Prof Margaret Hellard
Journal:  Lancet Reg Health West Pac       Date:  2021-11-23

3.  Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.

Authors:  Aaron G Lim; Nick Scott; Josephine G Walker; Saeed Hamid; Margaret Hellard; Peter Vickerman
Journal:  PLoS Med       Date:  2021-10-19       Impact factor: 11.069

Review 4.  A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis.

Authors:  Wei Zhang; Mahmoud Aryan; Steve Qian; Roniel Cabrera; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2021-06-19

5.  Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.

Authors:  Margaret Hellard; Alisa Pedrana; Bridget Draper
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-04-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.